Evidence map›Paper›PMID 33106957›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2021

Advantages and challenges for noninvasive atrial fibrillation ablation.

Masaaki Shoji, Koji Inaba, Jun Itami, Minoru Hamada, Hiroyuki Okamoto, Takeshi Iwasa, Takeshi Ushigusa, Masayuki Yoshida, Taka-Aki Matsuyama, Takayuki Otsuka and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Radiation therapy for ventricular arrhythmias.Journal of medical imaging and radiation oncology · 2024
    Review
  3. When radiation meets the heart: Future of stereotactic body radiation therapy for hypertrophic obstructive cardiomyopathy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Masaaki ShojiDepartment of Cardiovascular Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. shoji.sgh@me.com.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jun ItamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Minoru HamadaDepartment of Radiological Technology, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki OkamotoDepartment of Medical Physics, National Cancer Center Hospital, Tokyo, Japan.
Takeshi IwasaDepartment of Cardiovascular Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.
Takeshi UshigusaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Masayuki YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Taka-Aki MatsuyamaDepartment of Legal Medicine, Showa University School of Medicine, Tokyo, Japan.
Takayuki OtsukaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.
Koichiro KumagaiHeart Rhythm Center, Fukuoka Sanno Hospital, Fukuoka, Japan.
Kenzo HiraoDivision of Cardiovascular Medicine, AOI Universal Hospital, Kanagawa, Japan.
Patrick MaguireMedDevice Pharma LLC, Menlo Park, CA, USA.
Pierre QianCardiac Arrhythmia Service, Brigham and Women's Hospital, Boston, MA, USA.
Edward GardnerCyberheart, Inc., Mountain View, CA, USA.
Paul C ZeiCardiac Arrhythmia Service, Brigham and Women's Hospital, Boston, MA, USA.
Tokyo National Hospital · JPBrigham and Women's Hospital · USCardiovascular Institute Hospital · JPShowa University · JP

Funding

Cyberheart Inc. none
6 · The paper itself

Abstract

purposeAlthough catheter ablation is an effective therapy for atrial fibrillation (AF), risks remain and improved efficacy is desired. Stereotactic radiotherapy is a well-established therapy used to noninvasively treat malignancies with precision. We sought to evaluate stereotactic arrhythmia radioablation (STAR) as a therapeutic option for treating AF. METHODS AND

resultsThree cancer patients with drug refractory AF were enrolled. Planning software using 3-D CT of the left atrium was used to design a desired ablation volume encompassing antral circumferential pulmonary vein isolation, roof and floor lines to create a "box" lesion set. After planning, patients were treated in the radioablation suite. STAR was able to deliver the intended radiation dose to the target in all 3 patients. No complications were observed over a follow-up period of 24 months. One patient with paroxysmal AF died from deterioration of cancer. The autopsy revealed evidence of fibroblasts and fibrogenesis in the region of atrial tissues targeted with radioablation. In one of these patients, left atrial posterior wall electrograms recorded from the esophagus before and 3 months after STAR indicated successful electrical isolation.

conclusionsThis is the first report of non-invasive radioablation of the left atrium with demonstration of successful electrical isolation. Although STAR may be safe and effective in delivering ablative energy to the left atrium, further evaluation is warranted regarding effectiveness.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsHeart AtriaHumansTreatment OutcomeAblationAtrial fibrillationNew technologyNoninvasive ablationRadioablation

Identifiers

PMID33106957
OpenAlexW3093842775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.